Method for predicting sensitivity of cervical cancer patient subjected to paclitaxel and cis-platinum adopted chemotherapy

A prediction method and technology of cervical cancer, applied in the medical field, can solve problems such as cervical lesion degeneration, cervical signal confusion, necrosis, etc.

Inactive Publication Date: 2015-06-24
HARBIN MEDICAL UNIVERSITY
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The main problem with NACT treatment at present is that it is difficult to accurately reflect the effect of treatment by imaging after premenstrual chemotherapy. The reason is that cervical lesions may undergo degeneration, necrosis, and fibrosis after premenstrual chemotherapy, resulting in mixed signals of the cervix. , it is difficult to distinguish on conventional MRI plain scan images, resulting in large deviations in the evaluation results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for predicting sensitivity of cervical cancer patient subjected to paclitaxel and cis-platinum adopted chemotherapy
  • Method for predicting sensitivity of cervical cancer patient subjected to paclitaxel and cis-platinum adopted chemotherapy
  • Method for predicting sensitivity of cervical cancer patient subjected to paclitaxel and cis-platinum adopted chemotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.

[0024] Please refer to Figure 6 , Figure 6 It is a flowchart of a method for predicting chemosensitivity of cervical cancer patients using paclitaxel and cisplatin in an embodiment of the present invention.

[0025] From August 2009 to October 2010, the inventor conducted a prospective cohort study on multiple patients as research objects.

[0026] Inclusion criteria: (1) cervical squamous cell carcinoma confirmed by cervical biopsy; (2) FIGO...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

A method for predicting sensitivity of a cervical cancer patient subjected to paclitaxel and cis-platinum adopted chemotherapy comprises the steps: S1, preopreative examination is performed; S2, nidus analysis is performed; S3, mathematical statistics is performed; S4 sensitivity judgment is performed, namely serum SCC-Ag level analysis and post-chemotherapy MRI measurement are performed to judge chemotherapy sensitivity so as to determine whether a drug resistance rule is subjected to a postoperative pathological measurement result or not, it is confirmed that the patient is drug-sensitive if the drug resistance rule is subjected to the postoperative pathological measurement result, and it is confirmed that the patient is drug-resistant if the drug resistance rule is not subjected to the postoperative pathological measurement result. An experimental result of drug resistance analysis performed by means of the method for predicting the sensitivity of the cervical cancer patient subjected to the paclitaxel and cis-platinum adopted chemotherapy shows that change of the serum SCC-Ag level has close relationship with the sensitivity of cervical squamous cell neoadjuvant chemotherapy, important information can be provided for judgment on drug resistance of the patient, SCC-Ag and magnetic resonance imaging can be jointly and clinically utilized to assess the chemotherapy sensitivity, and the prediction accuracy is obviously higher than the prediction accuracy of an MRI imageology method widely and clinically used at present.

Description

technical field [0001] The invention relates to the field of medical technology, and more specifically relates to a method for predicting chemotherapy sensitivity of cervical cancer patients using paclitaxel and cisplatin. Background technique [0002] Due to the large size of the tumor, locally advanced cervical cancer brings certain difficulties to surgery, and the incidence of intraoperative bleeding and surgical complications is high. Simple surgery or radiotherapy is not easy to control, prone to lymph node metastasis or distant metastasis, and the five-year survival rate Low. [0003] Recently, neoadjuvant chemotherapy (NACT) has been considered as a new and promising treatment for locally advanced (stage Ib-IIb) cervical cancer. The results of the study showed that for patients with the same tumor clinical stage, preoperative neoadjuvant chemotherapy was more likely to shrink the tumor than simple radical surgery, and could reduce intraoperative bleeding and complica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61B5/055A61B19/00G01N33/48
Inventor 侯艳印明柱孙凤宇娄阁李康
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products